Journal of Alzheimer’s Disease 31 (2012) 13–20
DOI 10.3233/JAD-2012-120361
IOS Press
13
Risk of Alzheimer’s Disease Biological
Misdiagnosis Linked to Cerebrospinal
Collection Tubes
Armand Perret-Liaudeta,b,∗ , Mathieu Pelpelc , Yannick Tholancea , Benoit Dumonta ,
Hugo Vandersticheled , Willy Zorzie , Benaissa ElMoualije , Susanna Schraenb,f , Olivier Moreaudg ,
Audrey Gabelleh , Eric Thouvenoth , Catherine Thomas-Anterioni , Jacques Touchonh ,
Pierre Krolak-Salmona , Gabor G. Kovacsj , Arnaud Coudreusek , Isabelle Quadrioa
and Sylvain Lehmannb,h,∗
a Neurobiologie,
CMRR, Gériatrie, Hospices Civils de Lyon, Université Lyon 1 – CNRS UMR5292 – INSERM
U1028, Lyon, France
b Société Française de Biologie Clinique (SFBC), France
c Technical and QA Department, Innogenetics, Les Ulis, France
d ADx NeuroSciences, Technologiepark, Gent, Belgium
e Human Histology-CRPP, University of Liège, Liège, Belgium
f CHU de Lille, France; INSERM, U837, France
g CMRR, CHU de Grenoble, France
h CHU de Montpellier, IRB, INSERM-UM1 1040, INSERM U1061, France
i CMRR, Neurologie, CHU de Saint-Etienne, France
j Institute of Neurology, Medical University of Vienna, Vienna, Austria
k Centre de Transfert de Technologie du Mans, Le Mans, France
Handling Associate Editor: Julien Dumurgier
Accepted 19 March 2012
Abstract. Tau proteins and amyloid- (A) peptides are the current recognized cerebrospinal fluid (CSF) biomarkers used as an
aid in the diagnosis of Alzheimer’s disease (AD). However, there is no consensus on their clinical use due to non-qualified cut-off
values, probably related to the observed high pre-analytical and analytical variability. Standardized pre-analytical protocols have
therefore been proposed. Importantly, these recommend the use of polypropylene collection/sampling tubes while, to date, no
broad comparison of these types of tubes has been conducted. In this study, we first compared, as part of a real clinical workflow,
the impact of four different collection tubes on the CSF concentration of A peptides (A42 , A40 ) and total (hTau) and phosphorylated (P-Tau181P) tau proteins measured using routine ELISA kits. We then extended this study to 11 polypropylene tubes used
by different clinical laboratories, and investigated their plastic polymer composition using differential scanning calorimetry and
Fourier Transformed Infrared spectroscopy. Significant concentration variations linked solely to the use of different types of tubes
were observed. This was particularly marked for A peptides, with >50% disparity occurring in less than five minutes. Polymer
∗ Correspondence
to: Sylvain Lehmann, Institut de Recherche en
Biothérapie, 80 Avenue Augustin Fliche, 34295 Montpellier, France.
E-mail: s-lehmann@chu-montpellier.fr and Armand Perret-Liaudet,
Service de Neurobiologie, Hospices Civils de Lyon, 69677 Bron,
France; E-mail: E-mail: armand.perret-liaudet@chu-lyon.fr.
ISSN 1387-2877/12/$27.50 © 2012 – IOS Press and the authors. All rights reserved
14
A. Perret-Liaudet et al. / Alzheimer’s Disease Biological Misdiagnosis
composition analysis revealed that most polypropylene tubes were in fact copolymers with at least polyethylene. There was no
clear correlation between tube composition and pre-analytical behavior. Our results show that the use of polypropylene tubes
does not guarantee satisfactory pre-analytical behavior. They also point to collection/sampling tubes being a major pre-analytical
source of variability that could impact the significance of AD biological diagnosis.
Keywords: Alzheimer’s disease, cerebrospinal fluid, collection tubes, standardization
INTRODUCTION
Total tau protein (hTau), its phosphorylated isoform at position 181 (p-Tau181P), and amyloid- (A)
peptides (A42 and A40 ) are the current accepted
cerebrospinal fluid (CSF) biomarkers used as an aid
in the diagnosis of Alzheimer’s disease (AD) [1–5].
They help characterize atypical phenotypes, stratify
patients in clinical trials, and predict AD conversion
in prodromal forms [4, 6, 7]. Due notably to important
between-center variability [2, 8, 9], there is no consensus on their use and their cut-off values to define a CSF
AD signature. Investigation of pre-analytical events
affecting the levels of these biomarkers identified delay
of processing, storage in different types of tubes,
volume per tube, dilution with detergent-containing
buffer, plasma contamination, and heat treatment as
significant factors [10–13].
To minimize pre-analytical and analytical errors,
standardized operating procedures have been proposed
[8, 10, 11]. Importantly, they all recommend the use of
polypropylene tubes instead of polystyrene or glass.
However, only a descriptive study on influence of collection tubes onto the CSF A42 was conducted [14]. In
a recent letter we reported major differences between
collection tubes [15]. Here, we significantly extended
this initial study. We completed the comparison in a
real clinical workflow using four different collection
tubes. We also extended our study of 11 polypropylene tubes, looking at their biomarker performance in
relation with their plastic polymer composition.
Our results show that the use of polypropylene tubes
does not guarantee satisfactory pre-analytical behavior.
They also point to collection/sampling tubes being a
major pre-analytical source of variability that could
impact the significance of AD biological diagnosis.
MATERIALS AND METHODS
Study participants
Samples originated from biobanks generated in
two French Clinical and Research Memory Centres
(CMRRs) specialized in the care of cognitive disorders based in Lyon and Montpellier. Recruited patients
gave their written informed consent to participate in the
biobanks (registered # DC-2008-417). As the focus
of this study was analytical, samples were selected
to cover the different neurochemical situations corresponding to different diagnoses, and with variable
concentrations of biomarkers (Fig. 1).
CSF sampling and analysis
In a first series of experiments (Figs. 1 and 2),
CSF from 12 patients was collected directly in four
different types of tubes (2 mL per tube): ST-PP (Sarstedt, 10 mL, polypropylene, ref. 62.610.201); HE-PS
(Fisher Scientific hemolysis tube, 5 mL, polystyrene,
ref. W1773X); BD-PE (Becton Dickinson, 14 mL,
polystyrene, ref. 352095), and BD-PP (Becton Dickinson, 15 mL, polypropylene, ref. 352096). Collection
tubes were transported on ice to the laboratory and processed immediately by centrifugation (10 min, 1000 g).
Samples were divided into 0.5 mL aliquots in
polypropylene Eppendorf tubes (Protein LoBind, ref:
0030108.116.), stored at −80◦ C (less than 6 month),
and thawed immediately before quantification. In some
cases (Fig. 2A, B), freshly thawed samples were distributed in ST-PP tubes for the indicated period of time
at 2–8◦ C, or were supplemented with human albumin
for the indicated final concentrations and kept for 1 h
in ST-PP tubes before measurement.
In a second series of experiments (Fig. 3, Tables 2),
six non-hemorrhagic CSF samples were collected
directly in the tube J (Table 1), transported in less than
15 min to the laboratory and processed immediately
by centrifugation (10 min, 1000 g). After homogenization, 300 l of the supernatant was distributed in every
one of the 11 tubes (see Table 1 for description of
tubes) and left for 15 min (T1) or 24 h (T2) at 2–8◦ C.
They were then stored at −80◦ C and thawed before
immediate quantification.
CSF A42 , A40 , hTau, and p-Tau181P concentrations were measured using standardized commercially
available INNOTEST® /IBL sandwich ELISA tests
A. Perret-Liaudet et al. / Alzheimer’s Disease Biological Misdiagnosis
15
Fig. 1. Individual AD biomarker results from four different tube types. CSF from twelve patients was collected in four different types of tubes:
BD-PP, ST-PP, BD-PE, and HE-PS. After CSF processing, CSF A42 , hTau, p-Tau181P, and A40 were measured using commercially available
ELISA tests. For A40 one sample is missing. Note: results are expressed as the mean of two values. Variability between most sample duplicates
was in the range of the intra-assay CVs (from 2 to 8%). Some duplicates corresponding to low values were between 8 and 15%. Statistical
analysis showed that the four tubes all differs (p-values below 0.05) for CSF A42 and A40 . For hTau, only BD-PE differs from BD-PP and
ST-PP while for p-Tau181P, HE-PS differs from the tree other tubes. A, amyloid- protein; hTau, total Tau protein; p-Tau181P, Tau protein
phosphorylated at position 181.
according to the supplier’s instructions (Innogenetics,
Ghent, Belgium). To reduce variability, the analysis
of each series was performed within same experiment
using the same batch of kits. Intra-assays CVs were
<5% for As and p-Tau181P, and <8% for hTau.
Statistical analyses
Statistical analyses were performed and graphs prepared using XLSTAT and MedCalc (7.3) software.
Graphical results were presented as medians and
interquartile ranges. The impact of tube type was
assessed using a non-parametric test on the percentage
of concentration deviation for each tube to the average
concentration value for each CSF sample. A KruskalWallis test was used for comparison of k samples with a
significance level set at 5%. The tubes were compared
two by two with a bilateral test using the Conover-Iman
procedure.
Tube analysis
Physical analysis of the tubes was performed using
two methods [16]. Differential scanning calorimetry,
which is a measurement of a phase change of the
material, those phase changes being characteristic for a
material; melting points were measured and compared
to polyolefin references. Fourier Transformed Infrared
spectroscopy measures the absorption by a sample of
polychromatic radiation in the infrared domain, this
absorption being characteristic of the chemical groups
present in the sample. Thus, the spectrum obtained is
specific to the sample’s material or to the material family. The spectra were acquired in reflexion mode giving
a surface analysis with a probe depth of 1 to 5 m.
RESULTS
To investigate pre-analytical variations linked solely
to sampling tubes, CSF samples from 12 patients
16
A. Perret-Liaudet et al. / Alzheimer’s Disease Biological Misdiagnosis
Fig. 2. Median AD biomarker results using four different tube types, along with the effect of time delay and protein concentrations on the
results (in %). A) CSF from twelve patients was collected in four different types of tubes: BD-PP, ST-PP, BD-PE. and HE-PS. CSF A42 , hTau,
p-Tau181P, and A40 , were measured using commercially available ELISA tests (Fig. 1). For each individual sample, measured concentrations
were converted as a percentage of the mean of the values obtained in the four tubes. Results are presented as medians and interquartile ranges.
B) Four freshly thawed CSF samples with protein content ranging from 0.4 to 0.6 g/L were supplemented with human albumin to raise their
protein concentration by 0, 0.5, 1.0, and 1.5 g/L. These samples were then distributed in ST-PP tubes and left for 1 h at 2–8◦ C before A42
measurement. The graph reports the percentage concentration remaining of the initial A42 values. C) Four freshly thawed CSF samples were
distributed in ST-PP tubes for the indicated period of time at 2–8◦ C. The graph reports the percentage concentration remaining of the initial
A42 values.
enrolled in an ethically approved study were directly
(from the lumbar puncture needle) collected in four
different types of tubes: two polypropylene tubes, one
polystyrene tube, and one polyethylene tube. hTau,
p-Tau181P, A42 , and A40 concentrations were then
measured in parallel (Fig. 1).
When the results were expressed as a percentage
of the median value obtain in the four tubes (Fig. 2),
biomarkers concentration showed major variations that
were significantly different in many cases in particular for A peptides (Fig. 1). Median values for A42
peptides were for example of 80%, 137%, 81%, and
99% in BD-PP, ST-PP, BD-PE, and HE-PS tubes,
respectively. In individual patient samples (Fig. 1),
this effect was present over the whole range of A
values. These data confirmed and extended previous
observation by Pica-Mendez et al. [14].
In summary, much higher A42 and A40 concentrations were observed in ST-PP tubes compared to
the other tubes. Statistical differences between non
polypropylene tubes were also observed for hTau (HEPS) and p-Tau181P (BD-PE) (Fig. 1). This clearly
illustrated that each tube has its own pre-analytical
property.
In contrast with common knowledge and recommendations, it was clear that using polypropylene
tubes did not always result in optimal pre-analytical
behavior. Importantly, the type of tube used for the
same patient could dramatically change the interpretation of the biomarker results, leading therefore to
possible AD misdiagnosis (see individual concentration values on Fig. 1). hTau and p-Tau181P were,
however, less affected by the type of tubes, confirming
the importance of evaluating A peptides concentration in combination with these biomarkers.
To further explain the role of collection tubes on
resulting biomarker values, we selected 11 different
commercially available polypropylene collection tubes
(Table 1), some of them being used by different clinical teams in the AD field. We performed an evaluation
17
A. Perret-Liaudet et al. / Alzheimer’s Disease Biological Misdiagnosis
Fig. 3. Effect of time delay on median AD biomarker results from 11 different tube types (in %). After collection in one tube (J, Table 1) and
centrifugation, six CSF supernatants samples were homogenized and distributed into 11 different tubes (A to K, see Table 1) and left at 2–8◦ C for
15 min (T1) or for 24 h (T2) before A42 , hTau, and p-Tau181P were measured using commercially available ELISA tests. For each individual
sample, the measured concentrations were converted as a percentage of the mean of the values obtained in the 11 tubes. Results are presented
as medians and interquartile ranges. Statistical analysis showed no differences (p-values below 0.05) between T1 and T2 in the 11 tubes. A,
amyloid- protein; hTau, total Tau protein; p-Tau181P, Tau protein phosphorylated at position 181.
Table 1
Impact of polypropylene collection tubes on AD biomarkers and surface polymer composition analysis using differential scanning calorimetry
and Fourier Transformed Infrared spectroscopy
Tube
Provider
A
B
C
D
E
F
G
H
I
J
K
Greiner
Greiner
Deltalab
Evergreen
CML
Sarstedt
Sarstedt
Falcon
Nalgene
Falcon
Gosselin
Catalog numbers
Vol (mL)
Peak maximum (◦ C)
Peaks super-position
18 82 80
18 82 81
401402
222-3529-G8D
TC15PP
629.924.284
62.610.201
BD 35 2006
34 28 05
BD 35 2096
TK75-085
15
15
12
30
15
10
10
14
2
15
5
151.61
150.75
149.99
15.32
150.39
149.83
150.16
150.54
151.63
150.75
168.25
2
2
2
2
2
3
3
2
3
2
1
Identification
PP-PE copolymer
PP-PE copolymer
PP-PE copolymer
PP-PE copolymer
PP-PE copolymer
PP-PE +?
PP-PE +?
PP-PE copolymer
PP-PE +?
PP-PE copolymer
PP
Six CSF supernatants of freshly collected samples were distributed in to the 11 tubes for 15 min and A42 , hTau, and p-Tau181P were measured
using commercially available ELISA tests. For each individual sample, the measured concentrations were converted as a percentage of the mean
of the values obtained in the 11 tubes. The median of the different percentage are reported in the table. PP, polypropylene; PE, polyethylene.
18
A. Perret-Liaudet et al. / Alzheimer’s Disease Biological Misdiagnosis
Table 2
Statistical differences between values in the 11 tubes (A to K, see Table 1 and Fig. 3)
A1-42
A
B
C
D
E
F
G
H
I
J
K
A
B
C
D
E
F
G
H
I
J
K
1
0.429
1
<0.0001
<0.0001
1
<0.001
0.003
<0.0001
1
0.159
0.531
<0.0001
0.018
1
0.448
0.124
<0.0001
<0.0001
0.033
1
<0.0001
<0.0001
0.064
<0.0001
<0.0001
<0.0001
1
0.029
0.154
<0.0001
0.109
0.419
0.004
<0.0001
1
<0.0001
<0.0001
0.895
<0.0001
<0.0001
<0.0001
0.084
<0.0001
1
0.003
<0.001
0.022
<0.0001
<0.0001
0.026
<0.0001
<0.0001
0.016
1
0.001
<0.0001
0.051
<0.0001
<0.0001
0.010
<0.001
<0.0001
0.038
0.716
1
1
0.197
1
0.414
0.038
1
0.106
0.736
0.017
1
0.962
0.181
0.442
0.096
1
0.035
0.396
0.004
0.608
0.031
1
0.166
0.923
0.030
0.810
0.152
0.452
1
0.314
0.773
0.071
0.532
0.292
0.257
0.700
1
0.797
0.299
0.285
0.171
0.760
0.062
0.257
0.452
1
0.035
0.396
0.004
0.608
0.031
1.000
0.452
0.257
0.062
1
0.087
0.665
0.013
0.923
0.079
0.677
0.736
0.471
0.144
0.677
1
1
0.510
1
0.211
0.551
1
0.748
0.344
0.132
1
0.600
0.916
0.501
0.419
1
0.355
0.789
0.741
0.231
0.719
1
0.043
0.165
0.424
0.026
0.154
0.260
1
0.267
0.648
0.887
0.169
0.590
0.850
0.347
1
0.070
0.241
0.561
0.042
0.222
0.363
0.826
0.470
1
0.741
0.741
0.355
0.525
0.834
0.551
0.088
0.433
0.135
1
0.046
0.175
0.442
0.027
0.162
0.273
0.975
0.363
0.850
0.094
1
hTau
A
B
C
D
E
F
G
H
I
J
K
pTau
A
B
C
D
E
F
G
H
I
J
K
p-values are reported, values below 0.05 are in bold italics.
of their impact on the three classical AD biomarkers,
as well as carrying out a surface polymer composition analysis using differential scanning calorimetry
and Fourier Transformed Infrared spectroscopy. This
revealed surprising results with only one tube consisting of pure polypropylene, the others being copolymers
with at least polyethylene; even-though they were all
labeled as polypropylene (Table 1). Regulations in
fact allow companies to label tubes as being purely
polypropylene even in the presence of other polymers
or surface treatment. Incidentally, the exact polymer
composition of the different tubes was not disclosed
by most of the commercial providers.
Using a series of fresh (unfrozen) CSF samples
from 6 patients, we then distributed them between the
11 tubes and waited 15 min (T1) or 24 h (T2) before
processing the samples using the same analytical conditions (Table 2). This revealed significant differences
between tubes (Table 2) with maximum median variations of −48%/+31%, −8%/+8%, and −4%/+6%, for
A42 , hTau, and p-Tau181P, respectively.
When hTau and p-Tau181P were in the range of
acceptable and observed analytical variations for these
biomarkers, differences in A42 concentrations clearly
exceeded them. The effect was present after 15 min
(T1), and an additional 24 h (T2) incubation time
at 2–8◦ C did not significantly change these values
(Fig. 3).
Adsorption of the biomarkers on the tube surface was the most likely explanation for this “tube
effect” [17]. This explanation is consistent with previous unpublished observations suggesting that CSF
biomarker levels in samples with high protein content
(>1.5 g/L) were not changed by the type of collection tube, especially in comparison with samples with
low protein content. To confirm this observation, we
A. Perret-Liaudet et al. / Alzheimer’s Disease Biological Misdiagnosis
confirmed that artificially raising the protein content
of CSF samples resulted in a disappearance of the tube
effect (Fig. 1B). This was also coherent with the time
course of this effect that was tested in the tube with
the apparent higher A values (ST-PP, Fig. 1C). This
experiment revealed a 20% decrease in A peptides
concentration as early as 5 min after contact with the
tube. This means that when CSF is in contact with
a tube, A peptide values drop almost immediately,
and this effect is iterative (values drops again when
put in a new tube; not shown). Importantly, after these
first 5 min, the impact of additional time (24 and 48 h),
mimicking a pre-analytical delay, was minimal and not
significant up to 48 h (Figs. 1C and 3).
Surprisingly, the pure polypropylene tube (tube K)
did not give the best results and differences between
tubes suggested that additional surface treatment could
also change the adsorption properties of the tubes.
DISCUSSION
The high pre-analytical sensibility of A to different
polymer/plastic surfaces is an important observation to
take into account. Transfer of CSF in to different tubes
during processing or storage can result in a 20% to
60% decrease in measured concentrations. In addition,
analytical protocols often contain intermediate steps
involving transfer of CSF samples into new tubes or
plates, resulting in possible errors. This is true, not only
for A42 , but also for other A peptides (A40 , A38 ,
not shown), which are of interest for the diagnosis of
other neurological diseases [18]. Selection of collection tubes that would preserve the best A peptides
content would therefore make sense.
Adsorption of these analytes to the tube walls
is the most likely explanation for these phenomena. An interesting trend was observed since some
tubes that performed better for p-Tau181P were the
worst for A42 (tubes D and A). This suggests that
the hydrophilic/hydrophobic balance of the analytes
plays an important role in this phenomenon: the more
hydrophobic A42 peptide is greatly adsorbed by some
of the tubes. On the other hand, probably due to its
high content in anionic phosphate groups, p-Tau181P
which is more hydrophilic, is less adsorbed by the
tubes which adsorbed the A42 protein. Hydrophilicity
due to the polymer surface composition is an important point in understanding the adsorption of proteins
but other parameters may affect this absorption such
as the polymer surface charge in regard with the isoelectric point of the protein, or the surface roughness
19
[16, 19, 20]. It has been shown that changing both
the hydrophilicity and the charge of the surface may
lead to great improvement in the protein recovery [21]
underlying the fact that the tube composition and its
possible surface treatment is a key parameter in protein
adsorption.
In summary, our data indicated that the preanalytical impact of sampling/processing tubes has
to be particularly well optimized and harmonized for
multi-site studies and for the definition of relevant
and worldwide AD biomarker cut-off values. One way
to go is probably to define a consensus protocol that
specifically links cut-off values to given sampling tubes
and handling/analytical protocols.
ACKNOWLEDGMENTS
This work was in part realized in the framework
of a working group of the “Société Française de
Biologie Clinique” (SFBC). It was supported in part
for the Montpellier team by “France Alzheimer” and
through the National French Alzheimer effort (“Plan
Alzheimer”) and for the teams of Lyon, Le Mans,
Liège and Vienna by the EU FP6 Project Neuroscreen
LSHB-CZ-2006-037719 and by the Région Wallonne,
W2002134 and 14531-iPCRq contracts for Liège.
Mathieu Pelpel is an employee of the diagnostic
company Innogenetics® which commercializes diagnostic ELISA tests for Alzheimer Disease. In this
study, Mathieu Pelpel was not directly involved in the
setting or the design of the experiments.
Authors’ disclosures available online (http://www.jalz.com/disclosures/view.php?id=1230).
REFERENCES
[1]
[2]
[3]
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM,
Aisen PS, Petersen RC, Blennow K, Soares H, Simon A,
Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature
in Alzheimer’s disease neuroimaging initiative subjects. Ann
Neurol 65, 403-413.
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti
L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein
MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M,
Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J,
Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T,
Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow
K (2009) CSF biomarkers and incipient Alzheimer disease in
patients with mild cognitive impairment. JAMA 302, 385-393.
Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler
H, Frölich L, Schröder J, Peters O, Jessen F, Luckhaus C,
Perneczky R, Jahn H, Fiszer M, Maler JM, Zimmermann R,
Bruckmoser R, Kornhuber J, Lewczuk P (2007) Amyloid beta
20
[4]
[5]
[6]
[7]
[8]
[9]
[10]
View publication stats
A. Perret-Liaudet et al. / Alzheimer’s Disease Biological Misdiagnosis
peptide ratio 42/40 but not A beta 42 correlates with phosphotau in patients with low- and high-CSF A beta 40 load.
J Neurochem 101, 1053-1059.
Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky
ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC,
Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K,
O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S,
Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P
(2010) Revising the definition of Alzheimer’s disease: A new
lexicon. Lancet Neurol 9, 1118-1127.
Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A,
Winblad B, Vanderstichele H, Vanmechelen E, Blennow K
(1999) Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer
disease: Differences between early- and late-onset Alzheimer
disease and stability during the course of disease. Arch Neurol
56, 673-680.
Andreasen N, Blennow K (2005) CSF biomarkers for mild
cognitive impairment and early Alzheimer’s disease. Clin
Neurol Neurosurg 107, 165-173.
Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB, Alzheimer’s Disease
Neuroimaging Initiative (2010) Enrichment through biomarkers in clinical trials of Alzheimer’s drugs in patients with mild
cognitive impairment. Neurobiol Aging 31, 1443-1451.
Teunissen CE, Verwey NA, Kester MI, van Uffelen K,
Blankenstein MA (2010) Standardization of assay procedures
for analysis of the CSF biomarkers amyloid beta(1-42), tau,
and phosphorylated tau in Alzheimer’s disease: Report of
an international workshop. Int J Alzheimers Dis 2010, pii:
635053.
Mattsson N, Andreasson U, Persson S, Arai H, Batish SD,
Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N,
Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB,
Galasko D, Galimberti D, Hampel H, Handberg A, Heneka
MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel
C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E,
Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP,
Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C,
McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, rsquo O, Brien R, Otto M, Paraskevas
GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw
LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck
B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M,
Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer’s
association external quality control program for cerebrospinal
fluid biomarkers. Alzheimers Dement 7, 386-395.
Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsäter H,
Anckarsäter R, Andreasen N, Zetterberg H, Andreasson U,
Blennow K (2010) Confounding factors influencing amyloid
beta concentration in cerebrospinal fluid. Int J Alzheimers Dis
2010, pii: 986310.
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J, Wiltfang
J (2006) Effect of sample collection tubes on cerebrospinal
fluid concentrations of tau proteins and amyloid beta peptides.
Clin Chem 52, 332-334.
Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of
CSF-tau and csf-abeta42 as diagnostic markers for Alzheimer
disease in clinical practice. Arch Neurol 58, 373-379.
Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen
N, Zetterberg H, Blennow K (2011) Measurement of Abeta142 in cerebrospinal fluid is influenced by matrix effects.
J Neurochem 120, 325-333.
Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, Laterza
OF (2010) Nonspecific binding of Abeta42 to polypropylene
tubes and the effect of tween-20. Clin Chim Acta 411, 33.
Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, Elmoualij B, Schraen S, Moreaud
O, Gabelle A, Thouvenot E, Thomas-Anterion C, Touchon
J, Krolak-Salmon P, Kovacs GG, Coudreuse A, Quadrio I,
Lehmann S (2012) Cerebrospinal fluid collection tubes: A
critical issue for Alzheimer disease diagnosis. Clin Chem 58,
787-789.
Sweileh BA, Al-Hiari YM, Kailani MH, Mohammad HA
(2010) Synthesis and characterization of polycarbonates by
melt phase interchange reactions of alkylene and arylene
diacetates with alkylene and arylene diphenyl dicarbonates.
Molecules 15, 3661-3682.
Nakanishi K, Sakiyama T, Imamura K (2001) On the
adsorption of proteins on solid surfaces, a common but
very complicated phenomenon. J Biosci Bioeng 91, 233244.
Gabelle A, Roche S, Gény C, Bennys K, Labauge P, Tholance
Y, Quadrio I, Tiers L, Gor B, Boulanghien J, Chaulet C,
Vighetto A, Croisile B, Krolak-Salmon P, Perret-Liaudet A,
Touchon J, Lehmann S (2011) Decreased sAPP, A38 and
A40 cerebrospinal fluid levels in frontotemporal dementia.
J Alzheimers Dis 26, 553-563.
Duncan M, Lee J, Warchol M (1995) Influence of surfactants
upon protein/peptide adsorption to glass and polypropylene.
Int J Pharm 120, 179-188.
Poncin-Epaillard F, Mille C, Debarnot D, Zorzi W, Moualij
BE, Coudreuse A, Legeay G, Quadrio I, Perret-Liaudet A
(2011) Study of the adhesion of neurodegenerative proteins
on plasma-modified and coated polypropylene surfaces. J Biomater Sci Polym Ed 2011 Sep 28. [Epub ahead of print].
Zanini S, Riccardi C, Grimoldi E, Colombo C, Villa AM,
Natalello A, Gatti-Lafranconi P, Lotti M, Doglia SM (2010)
Plasma-induced graft-polymerization of polyethylene glycol
acrylate on polypropylene films: Chemical characterization
and evaluation of the protein adsorption. J Colloid Interface
Sci 341, 53-58.